Replimune Group (REPL) Competitors $10.39 -0.06 (-0.57%) Closing price 04:00 PM EasternExtended Trading$10.39 0.00 (0.00%) As of 04:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock REPL vs. RYTM, MRUS, CRNX, IMVT, VKTX, PTGX, SRRK, BHVN, CPRX, and MTSRShould you be buying Replimune Group stock or one of its competitors? The main competitors of Replimune Group include Rhythm Pharmaceuticals (RYTM), Merus (MRUS), Crinetics Pharmaceuticals (CRNX), Immunovant (IMVT), Viking Therapeutics (VKTX), Protagonist Therapeutics (PTGX), Scholar Rock (SRRK), Biohaven (BHVN), Catalyst Pharmaceuticals (CPRX), and Metsera (MTSR). These companies are all part of the "pharmaceutical products" industry. Replimune Group vs. Rhythm Pharmaceuticals Merus Crinetics Pharmaceuticals Immunovant Viking Therapeutics Protagonist Therapeutics Scholar Rock Biohaven Catalyst Pharmaceuticals Metsera Replimune Group (NASDAQ:REPL) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, community ranking, dividends, analyst recommendations, profitability, earnings, valuation and risk. Does the MarketBeat Community believe in REPL or RYTM? Rhythm Pharmaceuticals received 135 more outperform votes than Replimune Group when rated by MarketBeat users. Likewise, 67.71% of users gave Rhythm Pharmaceuticals an outperform vote while only 64.02% of users gave Replimune Group an outperform vote. CompanyUnderperformOutperformReplimune GroupOutperform Votes16964.02% Underperform Votes9535.98% Rhythm PharmaceuticalsOutperform Votes30467.71% Underperform Votes14532.29% Do analysts prefer REPL or RYTM? Replimune Group presently has a consensus price target of $19.43, indicating a potential upside of 89.64%. Rhythm Pharmaceuticals has a consensus price target of $69.46, indicating a potential upside of 27.38%. Given Replimune Group's stronger consensus rating and higher possible upside, equities analysts plainly believe Replimune Group is more favorable than Rhythm Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Replimune Group 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Rhythm Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.92 Which has more volatility & risk, REPL or RYTM? Replimune Group has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 2.3, suggesting that its stock price is 130% more volatile than the S&P 500. Do institutionals & insiders hold more shares of REPL or RYTM? 92.5% of Replimune Group shares are owned by institutional investors. 8.8% of Replimune Group shares are owned by company insiders. Comparatively, 5.6% of Rhythm Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is REPL or RYTM more profitable? Replimune Group has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -230.07%. Replimune Group's return on equity of -54.84% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Replimune GroupN/A -54.84% -42.97% Rhythm Pharmaceuticals -230.07%-367.36%-77.47% Which has higher valuation and earnings, REPL or RYTM? Rhythm Pharmaceuticals has higher revenue and earnings than Replimune Group. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReplimune GroupN/AN/A-$215.79M-$3.07-3.34Rhythm Pharmaceuticals$130.13M26.49-$184.68M-$4.35-12.54 Does the media refer more to REPL or RYTM? In the previous week, Rhythm Pharmaceuticals had 18 more articles in the media than Replimune Group. MarketBeat recorded 23 mentions for Rhythm Pharmaceuticals and 5 mentions for Replimune Group. Replimune Group's average media sentiment score of 1.52 beat Rhythm Pharmaceuticals' score of 0.33 indicating that Replimune Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Rhythm Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral SummaryReplimune Group beats Rhythm Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Remove Ads Get Replimune Group News Delivered to You Automatically Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart REPL vs. The Competition Export to ExcelMetricReplimune GroupBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$789.94M$3.02B$5.64B$7.88BDividend YieldN/A1.56%4.57%4.01%P/E Ratio-3.3428.9023.1218.71Price / SalesN/A427.38385.6791.56Price / CashN/A168.6838.1634.64Price / Book1.643.876.884.24Net Income-$215.79M-$71.95M$3.20B$247.06M7 Day Performance-5.31%-5.40%-2.58%-1.76%1 Month Performance-19.20%-11.90%1.93%-5.32%1 Year Performance25.40%-28.36%9.78%-0.51% Replimune Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)REPLReplimune Group3.8337 of 5 stars$10.39-0.6%$19.43+87.0%+26.7%$800.19MN/A-3.38210Positive NewsRYTMRhythm Pharmaceuticals4.4103 of 5 stars$53.72+3.2%$69.46+29.3%+28.0%$3.40B$130.13M-12.41140Analyst RevisionMRUSMerus2.3624 of 5 stars$48.77+3.2%$85.31+74.9%+0.2%$3.37B$36.13M-12.3537Analyst ForecastCRNXCrinetics Pharmaceuticals4.3203 of 5 stars$35.94+4.4%$74.30+106.7%-21.4%$3.34B$1.04M-9.64210Analyst ForecastIMVTImmunovant2.4751 of 5 stars$19.44-1.0%$41.70+114.5%-42.2%$3.30BN/A-7.42120VKTXViking Therapeutics4.3106 of 5 stars$29.28+1.1%$97.67+233.6%-68.6%$3.29BN/A-29.2820Analyst ForecastPTGXProtagonist Therapeutics3.6882 of 5 stars$52.53-0.2%$62.56+19.1%+73.6%$3.22B$434.43M19.75120Analyst ForecastPositive NewsHigh Trading VolumeSRRKScholar Rock3.9969 of 5 stars$33.81+2.3%$40.86+20.8%+115.9%$3.20B$33.19M-14.39140Analyst ForecastInsider TradeBHVNBiohaven3.8958 of 5 stars$30.97+8.5%$63.15+103.9%-50.3%$3.16BN/A-3.31239CPRXCatalyst Pharmaceuticals4.8224 of 5 stars$25.74+6.2%$32.29+25.4%+52.7%$3.13B$491.73M21.8180Positive NewsHigh Trading VolumeMTSRMetseraN/A$30.07+7.3%$47.00+56.3%N/A$3.10BN/A0.0081Earnings ReportNews Coverage Remove Ads Related Companies and Tools Related Companies Rhythm Pharmaceuticals Alternatives Merus Alternatives Crinetics Pharmaceuticals Alternatives Immunovant Alternatives Viking Therapeutics Alternatives Protagonist Therapeutics Alternatives Scholar Rock Alternatives Biohaven Alternatives Catalyst Pharmaceuticals Alternatives Metsera Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:REPL) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump’s Treasure Map [Pic inside]We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy REPL Stock Free REPL Stock Alerts